Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Bought by GHP Investment Advisors Inc.

GHP Investment Advisors Inc. raised its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 1,681.4% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 32,065 shares of the company’s stock after acquiring an additional 30,265 shares during the quarter. GHP Investment Advisors Inc.’s holdings in Teva Pharmaceutical Industries were worth $578,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the business. New Covenant Trust Company N.A. purchased a new position in Teva Pharmaceutical Industries in the first quarter valued at $28,000. EntryPoint Capital LLC acquired a new stake in Teva Pharmaceutical Industries in the 1st quarter valued at about $30,000. UMB Bank n.a. boosted its stake in shares of Teva Pharmaceutical Industries by 555.6% in the 3rd quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock valued at $44,000 after buying an additional 2,067 shares during the period. Beach Investment Counsel Inc. PA acquired a new position in shares of Teva Pharmaceutical Industries during the second quarter worth about $48,000. Finally, Byrne Asset Management LLC purchased a new stake in shares of Teva Pharmaceutical Industries during the second quarter worth approximately $52,000. Institutional investors and hedge funds own 54.05% of the company’s stock.

Insider Activity

In related news, insider Eric A. Hughes sold 24,537 shares of the firm’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $17.25, for a total transaction of $423,263.25. Following the transaction, the insider now owns 45,060 shares of the company’s stock, valued at $777,285. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Trading Down 1.9 %

NYSE:TEVA opened at $17.90 on Monday. The company has a market capitalization of $20.27 billion, a PE ratio of -43.66, a P/E/G ratio of 1.32 and a beta of 0.88. Teva Pharmaceutical Industries Limited has a 52-week low of $8.10 and a 52-week high of $19.08. The stock’s 50 day moving average price is $18.01 and its 200 day moving average price is $16.78. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 2.52.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Wednesday, July 31st. The company reported $0.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.55 by $0.03. The business had revenue of $4.16 billion for the quarter, compared to analyst estimates of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 2.73% and a positive return on equity of 39.66%. On average, research analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.33 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have commented on TEVA shares. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 17th. JPMorgan Chase & Co. increased their target price on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a report on Monday, October 21st. Barclays lifted their price target on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a report on Wednesday, October 23rd. UBS Group increased their price objective on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Finally, Argus upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 target price for the company in a research note on Wednesday, July 10th. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $19.67.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.